{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:36Z","timestamp":1792801356498,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40263-021-00878-x","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T21:04:44Z","timestamp":1638306284000},"page":"1317-1328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Nusinersen: A Review in 5q Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"35","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"878_CR1","unstructured":"US Library of Medicine. Genetics Home Reference: spinal muscular atrophy. 2020. http:\/\/ghr.nlm.nih.gov\/condition\/spinal-muscular-atrophy. Accessed 19 Apr 2021."},{"issue":"4","key":"878_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","volume":"14","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14(4):214\u201324.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"878_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/brainsci11091244","volume":"11","author":"S Brakemeier","year":"2021","unstructured":"Brakemeier S, Stolte B, Thimm A, et al. Assessment of bulbar function in adult patients with 5q-SMA Type 2 and 3 under treatment with nusinersen. Brain Sci. 2021;11(9):1244.","journal-title":"Brain Sci"},{"issue":"Cd006281","key":"878_CR4","first-page":"1","volume":"12","author":"RI Wadman","year":"2019","unstructured":"Wadman RI, van der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev. 2019;12(Cd006281):1\u201346.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Cd006282","key":"878_CR5","first-page":"1","volume":"1","author":"RI Wadman","year":"2020","unstructured":"Wadman RI, van der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020;1(Cd006282):1\u201397.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"878_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/NPM-200680","volume":"14","author":"JJ Volpe","year":"2021","unstructured":"Volpe JJ. Infantile spinal muscular atrophy: the potential for cure of a fatal disease. J Neonatal Perinatal Med. 2021;14(2):153\u20137.","journal-title":"J Neonatal Perinatal Med."},{"issue":"7","key":"878_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40263-018-0545-1","volume":"32","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs. 2018;32(7):689\u201396.","journal-title":"CNS Drugs"},{"issue":"11","key":"878_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"key":"878_CR9","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02386553. 2021. https:\/\/clinicaltrials.gov\/. Accessed 23 Aug 2021."},{"key":"878_CR10","unstructured":"Biogen Inc. New results from landmark NURTURE study show that pre-symptomatic SMA patients treated with SPINRAZA\u00ae (nusinersen) continue to demonstrate sustained benefit from treatment. 2020. https:\/\/www.biogen.com\/. Accessed 8 Oct 2021."},{"key":"878_CR11","unstructured":"Swoboda KJ, Sansone VA, De Vivo DC, et al. Preserved swallowing function in infants who initiated nusinersen treatment in the presymptomatic stage of SMA: results from the NURTURE study [abstract]. In: 2021 MDA Virtual Clinical & Scientific Conference. 2021."},{"issue":"10063","key":"878_CR12","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"18","key":"878_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"Suppl 22","key":"878_CR14","first-page":"S389","volume":"84","author":"N Kuntz","year":"2018","unstructured":"Kuntz N, Tizzano E, Topaloglu H, et al. Time to motor function response among nusinersen-treated infants from the ENDEAR study [abstract no. 141]. Ann Neurol. 2018;84(Suppl 22):S389\u201390.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"878_CR15","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.nmd.2020.08.263","volume":"30","author":"R Finkel","year":"2020","unstructured":"Finkel R, Kirschner J, Mercuri E, et al. Longer-term effects of nusinersen on motor function outcomes based on age at treatment initiation [abstract no P.264]. Neuromuscul Disord. 2020;30(Suppl 1):S123\u20134.","journal-title":"Neuromuscul Disord"},{"issue":"Suppl 1","key":"878_CR16","first-page":"23","volume":"63","author":"L Servais","year":"2021","unstructured":"Servais L, Finkel RS, Kirschner J, et al. Longer-term effects of nusinersen on motor function outcomes based on age at treatment initiation [abstract no. 29]. Dev Med Child Neurol. 2021;63(Suppl 1):23.","journal-title":"Dev Med Child Neurol"},{"key":"878_CR17","unstructured":"Servais L, Finkel RS, Castro D, et al. Predictive factors of nusinersen treatment response in infantile-onset spinal muscular atrophy: results from the ENDEAR\/SHINE studies [abstract]. In: 2021 MDA Virtual Clinical & Scientific Conference. 2021."},{"issue":"7","key":"878_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","volume":"28","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, et al. Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function. Neuromuscul Disord. 2018;28(7):582\u20135.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"878_CR19","first-page":"53","volume":"37","author":"S Messina","year":"2018","unstructured":"Messina S, Sframeli M, Bruno C, et al. Nutritional status in SMA type 1 over a 6 month follow-up in nusinersen expanded access program (EAP) [abstract]. Acta Myol. 2018;37(1):53\u20134.","journal-title":"Acta Myol."},{"issue":"3","key":"878_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","volume":"86","author":"M Pane","year":"2019","unstructured":"Pane M, Coratti G, Sansone VA, et al. Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol. 2019;86(3):443\u201351.","journal-title":"Ann Neurol"},{"issue":"3","key":"878_CR21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/acn3.51276","volume":"8","author":"M Pane","year":"2021","unstructured":"Pane M, Coratti G, Sansone VA, et al. Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients. Ann Clin Transl Neurol. 2021;8(3):548\u201357.","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"878_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"key":"878_CR23","unstructured":"Biogen Netherlands B.V. Spinraza 12 mg solution for injection: EU summary of product characteristics. 2021. http:\/\/www.ema.europa.eu\/. Accessed 16 Mar 2021."},{"issue":"S1","key":"878_CR24","first-page":"S67","volume":"8","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Longer-term treatment with nusinersen: results in later-onset spinal muscular atrophy from the SHINE study [abstract no. 265]. J Neuromuscular Dis. 2021;8(S1):S67.","journal-title":"J Neuromuscular Dis."},{"issue":"21","key":"878_CR25","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92(21):e2492\u2013506.","journal-title":"Neurology"},{"key":"878_CR26","unstructured":"Tulinius M, Darras B, Chiriboga C, et al. Longer-term improved\/maintained motor function in nusinersen-treated children with later-onset SMA in CS2\/CS12 and SHINE [abstract no EPR-279]. Eur J Neurol. 2021; 28(Suppl 1):394."},{"issue":"7","key":"878_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","volume":"31","author":"G Coratti","year":"2021","unstructured":"Coratti G, Pane M, Lucibello S, et al. Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen. Neuromuscul Disord. 2021;31(7):596\u2013602.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"878_CR28","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/acn3.51411","volume":"8","author":"MC Pera","year":"2021","unstructured":"Pera MC, Coratti G, Bovis F, et al. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8(8):1622\u201334.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"878_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317\u201325.","journal-title":"Lancet Neurol"},{"issue":"11","key":"878_CR30","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91(11):1166\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"878_CR31","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11(3):e317\u201327.","journal-title":"Neurol Clin Pract."},{"key":"878_CR32","first-page":"650635","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S, et al. Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA. Front Neurol. 2021;12:650635.","journal-title":"Front Neurol"},{"key":"878_CR33","first-page":"65032","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S, et al. Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front Neurol. 2021;12:65032.","journal-title":"Front Neurol"},{"key":"878_CR34","doi-asserted-by":"publisher","first-page":"175628642199890","DOI":"10.1177\/1756286421998902","volume":"14","author":"A Osmanovic","year":"2021","unstructured":"Osmanovic A, Ranxha G, Kumpe M, et al. Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy. Ther Adv Neurol Disord. 2021;14:1756286421998902.","journal-title":"Ther Adv Neurol Disord"},{"key":"878_CR35","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","volume":"63","author":"G Acsadi","year":"2021","unstructured":"Acsadi G, Crawford TO, Muller-Felber W, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study. Muscle Nerve. 2021;63:668\u201377.","journal-title":"Muscle Nerve"},{"issue":"148","key":"878_CR36","first-page":"1","volume":"15","author":"F Audic","year":"2020","unstructured":"Audic F, de la Banda MGG, Bernoux D, et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 2020;15(148):1\u201310.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"878_CR37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","volume":"33","author":"BT Darras","year":"2019","unstructured":"Darras BT, Farrar MA, Mercuri E, et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs. 2019;33(9):919\u201332.","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"878_CR38","first-page":"287","volume":"28","author":"M Farrar","year":"2021","unstructured":"Farrar M, Castro D, Finkel R, et al. Longer-term safety data in individuals with later-onset SMA support the favourable tolerability profile of nusinersen [abstract no. EPR-123]. Eur J Neurol. 2021;28(Suppl 1):287.","journal-title":"Eur J Neurol"},{"key":"878_CR39","unstructured":"Biogen Inc. SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information. 2020. http:\/\/www.fda.gov\/. Accessed 16 Mar 2021."},{"issue":"12","key":"878_CR40","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1007\/s00415-021-10569-8","volume":"268","author":"B Stolte","year":"2021","unstructured":"Stolte B, Nonnemacher M, Kizina K, et al. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J Neurol. 2021;268(12):4667\u201379.","journal-title":"J Neurol"},{"issue":"Suppl 1","key":"878_CR41","first-page":"S152","volume":"8","author":"V Sansone","year":"2021","unstructured":"Sansone V, Finkel R, Tulinius M, et al. Integrated analysis of annualized incidence of serious adverse events in infantile-onset SMA treated with nusinersen [abstract no. 765]. J Neuromuscular Dis. 2021;8(Suppl 1):S152\u20133.","journal-title":"J Neuromuscular Dis."},{"key":"878_CR42","unstructured":"Novartis Gene Therapies EU Limited. Zolgensma 2 \u00d7 1013 vector genomes\/mL solution for infusion: EU summary of product characteristics. 2021. http:\/\/www.ema.europa.eu\/. Accessed 17 Aug 2021."},{"key":"878_CR43","unstructured":"AveXis Inc. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi): US prescribing information. 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma. Accessed 25 May 2021."},{"issue":"11","key":"878_CR44","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79(11):1255\u201362.","journal-title":"Drugs"},{"key":"878_CR45","unstructured":"Roche Registration GmbH. Evrysdi 0.75 mg\/mL powder for oral solution: EU summary of product characteristics. 2021. http:\/\/www.ema.europa.eu\/. Accessed 25 May 2021."},{"key":"878_CR46","unstructured":"Genentech Inc. EVRYSDI\u00ae (risdiplam) for oral solution: US prescribing information. 2021. https:\/\/www.fda.gov\/. Accessed 25 May 2021."},{"issue":"17","key":"878_CR47","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Risdiplam: first approval. Drugs. 2020;80(17):1853\u20138.","journal-title":"Drugs"},{"issue":"7","key":"878_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jcm9072222","volume":"9","author":"S Messina","year":"2020","unstructured":"Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9(7):13.","journal-title":"J Clin Med"},{"issue":"4","key":"878_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1474-4422(20)30068-5","volume":"19","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Sansone V. Nusinersen in adults with spinal muscular atrophy: new challenges. Lancet Neurol. 2020;19(4):283\u20134.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"878_CR50","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.nmd.2021.07.301","volume":"31","author":"H Weststrate","year":"2021","unstructured":"Weststrate H, Stimpson G, Thomas L, et al. Bulbar function evolution in SMA type 1 children treated with nusinersen [abstract no. EP.276]. Neuromuscul Disord. 2021;31(Suppl 1):S133\u20134.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"878_CR51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1164\/rccm.201906-1175LE","volume":"200","author":"A LoMauro","year":"2019","unstructured":"LoMauro A, Mastella C, Alberti K, et al. Effect of nusinersen on respiratory muscle function in different subtypes of type 1 spinal muscular atrophy. Am J Respir Crit Care Med. 2019;200(12):1547\u201350.","journal-title":"Am J Respir Crit Care Med"},{"key":"878_CR52","doi-asserted-by":"publisher","unstructured":"Chacko A, Sly PD, Ware RS, et al. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3. Thorax. 2021. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216564.","DOI":"10.1136\/thoraxjnl-2020-216564"},{"issue":"1","key":"878_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13023-021-01822-4","volume":"16","author":"E Viscidi","year":"2021","unstructured":"Viscidi E, Wang N, Juneja M, et al. The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): results from a US electronic health records study. Orphanet J Rare Dis. 2021;16(1):207.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"878_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"878_CR55","first-page":"1300","volume":"25","author":"SD Pearson","year":"2019","unstructured":"Pearson SD, Thokala P, Stevenson M, et al. The effectiveness and value of treatments for spinal muscular atrophy: a summary from the Institute for Clinical and Economic Review\u2019s New England Comparative Effectiveness Public Advisory Council. J Manag Care Spec Pharm. 2019;25(12):1300\u20136.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"878_CR56","doi-asserted-by":"publisher","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma(R)) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9(1):1889841.","journal-title":"J Mark Access Health Policy."},{"issue":"6","key":"878_CR57","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2020.09.021","volume":"24","author":"TF Broekhoff","year":"2021","unstructured":"Broekhoff TF, Sweegers CCG, Krijkamp EM, et al. Early cost-effectiveness of onasemnogene abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 2021;24(6):759\u201369.","journal-title":"Value Health."},{"key":"878_CR58","unstructured":"UK National Institute for Health and Care Excellence. Nusinersen for treating spinal muscular atrophy: technology appraisal guidance [TA588]. 2019. https:\/\/www.nice.org.uk\/guidance\/ta588. Accessed 27 May 2021."},{"issue":"5","key":"878_CR59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","volume":"21","author":"DA Ollendorf","year":"2018","unstructured":"Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare conditions: no easy answers. Value Health. 2018;21(5):547\u201352.","journal-title":"Value Health."},{"key":"878_CR60","unstructured":"UK National Institute for Health and Care Excellence. NICE announces more people eligible for nusinersen following review of Managed Access Agreement. 2021. https:\/\/www.nice.org.uk\/. Accessed 31 May 2021."},{"issue":"5","key":"878_CR61","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6(5):932\u201344.","journal-title":"Ann Clin Transl Neurol"},{"issue":"Suppl 23","key":"878_CR62","first-page":"S122","volume":"86","author":"R Finkel","year":"2019","unstructured":"Finkel R, Sumner C, Darras B, et al. Association between plasma phosphorylated neurofilament heavy chain and efficacy endpoints in the nusinersen NURTURE study [abstract no. 173]. Ann Neurol. 2019;86(Suppl 23):S122.","journal-title":"Ann Neurol"},{"key":"878_CR63","doi-asserted-by":"crossref","unstructured":"Sumner CJ, Darras BT, Muntoni F, et al. Association of phosphorylated neurofilament heavy chain (pNF-H) levels with motor function achievement in individuals with spinal muscular atrophy (SMA) treated with nusinersen [abstract no. S27.009]. Neurology. 2019;92(15 Suppl 1).","DOI":"10.1016\/j.jns.2019.10.1268"},{"key":"878_CR64","doi-asserted-by":"crossref","unstructured":"Darras BT, Sumner CJ, Muntoni F, et al. Plasma phosphorylated neurofilament heavy chain levels over time in participants with infantile-and later-onset SMA: data from the SHINE study [abstract no. 1692]. Neurology. 2020;94(15 Suppl).","DOI":"10.1212\/WNL.94.15_supplement.1692"},{"issue":"2","key":"878_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/biomedicines8020021","volume":"8","author":"S Bonanno","year":"2020","unstructured":"Bonanno S, Marcuzzo S, Malacarne C, et al. Circulating myomiRs as potential biomarkers to monitor response to nusinersen in pediatric SMA patients. Biomedicines. 2020;8(2):21.","journal-title":"Biomedicines."},{"issue":"1","key":"878_CR66","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ppul.25142","volume":"56","author":"M G\u00f3mez-Garcia de la Banda","year":"2020","unstructured":"G\u00f3mez-Garcia de la Banda M, Amaddeo A, Khirani S, et al. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen. Pediatr Pulmonol. 2020;56(1):299\u2013306.","journal-title":"Pediatr Pulmonol"},{"key":"878_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","volume":"219","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Pirola A, Albamonte E, et al. Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen. J Pediatr. 2020;219:223-8.e4.","journal-title":"J Pediatr"}],"updated-by":[{"DOI":"10.1007\/s40263-021-00889-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00878-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00878-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00878-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T10:13:28Z","timestamp":1726222408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00878-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00878-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"3 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-021-00889-8","URL":"https:\/\/doi.org\/10.1007\/s40263-021-00889-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}